Add BrightSurf on Google Email

Scientists demonstrate utility of Bilateral Tumor Model for evaluating anti-cancer T-cell responses

A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.

SourceTokyo University of Science·JournalFrontiers in Immunology·TypeExperimental study·DateJan 19, 2022

Researchers reduce breast cancer metastasis in animal models by modifying tumor electrical properties

Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.

SourceTufts University·JournalEBioMedicine·TypeExperimental study·DateJan 11, 2022

UCLA-led study provides first indirect evidence that PSMA PET/CT surpasses conventional imaging in detecting occult prostate cancer spread and predicting long-term course and outcomes

A recent UCLA-led study provided indirect evidence that PSMA PET/CT improves risk-stratification and prognostic capabilities for high-risk prostate cancer patients. The study found that PSMA nomogram outperformed existing tools in predicting clinical outcomes, suggesting its significance in disease course prediction.

SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Network Open·TypeObservational study·DateDec 13, 2021

Elacestrant may improve outcomes for patients whose metastatic breast cancers progressed on prior endocrine therapy

In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.

Using genomics to match treatments improved outcomes for certain patients with metastatic breast cancer

The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.

CNIO researchers discover a new mechanism involved in early melanoma metastasis

CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalNature Cancer·TypeExperimental study·DateNov 25, 2021

Palmitic acid promotes cancer metastasis and leaves a more aggressive “memory” in tumour cells

A diet rich in palmitic acid makes tumor cells more aggressive and increases their metastatic capacity, a process that is responsible for 90% of cancer deaths. Exposure to palmitic acid leads to permanent epigenetic modifications in tumor cells, allowing them to conserve metastatic capacity even after the fatty acid is removed.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalNature·TypeExperimental study·DateNov 10, 2021

High cell membrane tension constrains the spread of cancer

Research reveals that cancer cells have softer membranes than normal cells, but stiffening them can prevent abnormal changes in structure and motility. Stiffened breast cancer cells lost the ability to spread to the lungs in mouse experiments, suggesting a potential strategy for cancer treatments.

SourceKobe University·JournalNature Communications·TypeExperimental study·DateNov 8, 2021

World-first clinical trial demonstrates focused ultrasound can deliver antibody therapy to breast cancer metastases in the brain

Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.

SourceFocused Ultrasound Foundation·JournalScience Translational Medicine·TypeRandomized controlled/clinical trial·DateOct 13, 2021

Research points to a strategy for overcoming colorectal cancers’ immunotherapy resistance

New research reveals that boosting numbers of immune cells called dendritic cells may be key to overcoming colorectal cancers' immunotherapy resistance. By augmenting dendritic cells in liver metastases, treatment led to increased cytotoxic T lymphocytes and made tumors sensitive to immune checkpoint inhibitors.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateOct 11, 2021

A protein causes significantly higher risk of severe cancer progression for men

A research team at TUM has discovered that the protein TIMP1 is associated with a significantly higher risk of liver metastasis and death in male patients, particularly those with pancreatic, colon, and melanoma cancers. This finding may lead to improved diagnosis and targeted therapy options for men.

SourceTechnical University of Munich (TUM)·JournalJournal of Experimental Medicine·TypeExperimental study·DateOct 5, 2021

Why don’t adrenal gland metastases respond to immunotherapy?

Researchers discovered that adrenal gland metastases are unresponsive to checkpoint inhibitors due to the secretion of corticosteroids. Surgical removal is the current best course of action for patients with these metastases. The study's authors hope to develop a nonsurgical treatment option in the future.

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of the National Comprehensive Cancer Network·DateSep 23, 2021

New study shows that different types of cancers are likely to spread to specific areas of the brain

Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.

SourceUniversity of Southern California - Health Sciences·JournalJournal of Neurosurgery·TypeComputational simulation/modeling·DateSep 23, 2021

Phase III POSEIDON trial shows positive results for patients taking chemotherapy plus durvalumab and tremelimumab

The Phase III POSEIDON trial demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with metastatic non-small cell lung cancer (mNSCLC) treated with chemotherapy plus durvalumab and tremelimumab. Durvalumab combined with tremelimumab and chemotherapy reduced the risk of death...

Increased survival with eye melanoma in clinical trial

A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.

SourceUniversity of Gothenburg·JournalNature Communications·TypeRandomized controlled/clinical trial·DateAug 30, 2021

High cholesterol fuels cancer by fostering resistance to a form of cell death

Researchers at Duke University Medical Center identified a mechanism where breast cancer cells use cholesterol to develop tolerance to stress, allowing them to resist ferroptosis and proliferate. This finding highlights the importance of lowering cholesterol in preventing cancer progression and offers new approaches for treatment.

SourceDuke University Medical Center·JournalNature Communications·TypeExperimental study·DateAug 24, 2021

Adoptive transfer of tumor-infiltrating lymphocytes may be less effective in patients with pretreated metastatic melanoma

Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...

SourceAmerican Association for Cancer Research·JournalClinical Cancer Research·DateAug 19, 2021

Researchers find circular RNA can inhibit metastasis of gastric cancer

A recent study by Chinese Academy of Sciences researchers found that circular RNA circURI1 inhibits the spread of gastric cancer cells. It achieves this by sequestering hnRNPM, modulating alternative splicing in gastric cancer cells. This breakthrough provides a new perspective on the molecular basis of cancer metastasis.

SourceChinese Academy of Sciences Headquarters·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateAug 19, 2021

Researchers identify mechanisms of resistance to drug for triple-negative breast cancer

Researchers at Massachusetts General Hospital have identified two separate genetic alterations that enable triple-negative breast cancer cells to develop resistance to a highly effective drug. The findings could help improve therapy and prolong survival for patients with this aggressive form of breast cancer.

SourceMassachusetts General Hospital·JournalCancer Discovery·TypeExperimental study·DateAug 17, 2021